Caribou Biosciences Inc

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on CRISPR genome editing. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA technology that enables precise editing for allogeneic cell therapies. The company is developing Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy in phase 1 trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy in phase 1 trials for relapsed or refractory multiple myeloma. Incorporated in 2011, it is headquartered in Berkeley, California.